Merrimack Pharmaceuticals (MACK) Stock News, Nov 5, 2020

Merrimack Pharmaceuticals, Inc. (MACK) reported its third quarter 2020 financial results, with a net loss of $1.0 million, or $0.08 per share, compared to a loss of $0.7 million in Q3 2019. General and administrative expenses significantly decreased to $1.0 million from $4.3 million in the prior year. Cash reserves as of September 30, 2020, were $15.8 million, down from $16.6 million at year-end 2019. The company is focused on cash conservation and expects potential milestone payments from Ipsen and Elevation Oncology, who continue patient enrollment in ongoing clinical trials.